These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 10928059)

  • 21. [Histone-deacetylases inhibitors: from TSA to SAHA].
    Peixoto P; Lansiaux A
    Bull Cancer; 2006 Jan; 93(1):27-36. PubMed ID: 16455503
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Histone deacetylase inhibitors--a new tool to treat cancer.
    Somech R; Izraeli S; J Simon A
    Cancer Treat Rev; 2004 Aug; 30(5):461-72. PubMed ID: 15245778
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cu2+ is required for pyrrolidine dithiocarbamate to inhibit histone acetylation and induce human leukemia cell apoptosis.
    Chen J; Du C; Kang J; Wang J
    Chem Biol Interact; 2008 Jan; 171(1):26-36. PubMed ID: 17961528
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epigenetic therapy in cancer: molecular background and clinical development of histone deacetylase and DNA methyltransferase inhibitors.
    Schneider-Stock R; Ocker M
    IDrugs; 2007 Aug; 10(8):557-61. PubMed ID: 17665331
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy.
    Carew JS; Giles FJ; Nawrocki ST
    Cancer Lett; 2008 Sep; 269(1):7-17. PubMed ID: 18462867
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Histone deacetylase inhibitors.
    Marks PA; Richon VM; Miller T; Kelly WK
    Adv Cancer Res; 2004; 91():137-68. PubMed ID: 15327890
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prospects: histone deacetylase inhibitors.
    Dokmanovic M; Marks PA
    J Cell Biochem; 2005 Oct; 96(2):293-304. PubMed ID: 16088937
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular basis of the anti-cancer effects of histone deacetylase inhibitors.
    Epping MT; Bernards R
    Int J Biochem Cell Biol; 2009 Jan; 41(1):16-20. PubMed ID: 18765293
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Histone deacetylase inhibitors: molecular mechanisms of action.
    Xu WS; Parmigiani RB; Marks PA
    Oncogene; 2007 Aug; 26(37):5541-52. PubMed ID: 17694093
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Focus on deacetylation for therapeutic benefit.
    Shabbeer S; Carducci MA
    IDrugs; 2005 Feb; 8(2):144-54. PubMed ID: 15696416
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors.
    Khan N; Jeffers M; Kumar S; Hackett C; Boldog F; Khramtsov N; Qian X; Mills E; Berghs SC; Carey N; Finn PW; Collins LS; Tumber A; Ritchie JW; Jensen PB; Lichenstein HS; Sehested M
    Biochem J; 2008 Jan; 409(2):581-9. PubMed ID: 17868033
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Histone deacetylase inhibitors: apoptotic effects and clinical implications (Review).
    Emanuele S; Lauricella M; Tesoriere G
    Int J Oncol; 2008 Oct; 33(4):637-46. PubMed ID: 18813776
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics.
    Gallinari P; Di Marco S; Jones P; Pallaoro M; Steinkühler C
    Cell Res; 2007 Mar; 17(3):195-211. PubMed ID: 17325692
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo.
    Weichert W; Röske A; Niesporek S; Noske A; Buckendahl AC; Dietel M; Gekeler V; Boehm M; Beckers T; Denkert C
    Clin Cancer Res; 2008 Mar; 14(6):1669-77. PubMed ID: 18347167
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The molecular mechanism of HDAC inhibitors in anticancer effects.
    Bi G; Jiang G
    Cell Mol Immunol; 2006 Aug; 3(4):285-90. PubMed ID: 16978537
    [TBL] [Abstract][Full Text] [Related]  

  • 36. p21Waf1/Cip1 is a common target induced by short-chain fatty acid HDAC inhibitors (valproic acid, tributyrin and sodium butyrate) in neuroblastoma cells.
    Rocchi P; Tonelli R; Camerin C; Purgato S; Fronza R; Bianucci F; Guerra F; Pession A; Ferreri AM
    Oncol Rep; 2005 Jun; 13(6):1139-44. PubMed ID: 15870934
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epigenetic mechanisms regulate stage differentiation in the minimized protozoan Giardia lamblia.
    Sonda S; Morf L; Bottova I; Baetschmann H; Rehrauer H; Caflisch A; Hakimi MA; Hehl AB
    Mol Microbiol; 2010 Apr; 76(1):48-67. PubMed ID: 20132448
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of type-specific anticancer histone deacetylase inhibitors: road to success.
    Noureen N; Rashid H; Kalsoom S
    Cancer Chemother Pharmacol; 2010 Sep; 66(4):625-33. PubMed ID: 20401613
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Histone deacetylase inhibitors: anticancer compounds.
    Smith KT; Workman JL
    Int J Biochem Cell Biol; 2009 Jan; 41(1):21-5. PubMed ID: 18845268
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Histone deacetylase inhibitors--new anticancer agents?].
    Yoshida M; Horinouchi S
    Tanpakushitsu Kakusan Koso; 2000 Apr; 45(6 Suppl):1090-5. PubMed ID: 10771678
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.